Equities Analysts Offer Predictions for Innoviva Q4 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Stock analysts at HC Wainwright cut their Q4 2026 EPS estimates for shares of Innoviva in a report released on Monday, June 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $0.54 per share for the quarter, down from their previous estimate of $0.55. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Innoviva’s Q1 2027 earnings at $0.51 EPS, Q2 2027 earnings at $0.61 EPS, Q3 2027 earnings at $0.59 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.36 EPS.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Innoviva had a return on equity of 33.33% and a net margin of 119.89%.The company had revenue of $97.99 million for the quarter, compared to the consensus estimate of $101.57 million.

Several other research analysts have also issued reports on the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Innoviva in a research note on Friday, March 27th. Wall Street Zen raised shares of Innoviva from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Finally, BTIG Research reiterated a “buy” rating and set a $42.00 target price on shares of Innoviva in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Innoviva Price Performance

Innoviva stock opened at $22.67 on Tuesday. The business has a 50 day simple moving average of $22.75 and a 200 day simple moving average of $21.84. The company has a debt-to-equity ratio of 0.19, a current ratio of 21.13 and a quick ratio of 20.07. The company has a market capitalization of $1.67 billion, a PE ratio of 3.77 and a beta of 0.35. Innoviva has a one year low of $16.52 and a one year high of $25.15.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its stake in shares of Innoviva by 82.8% in the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 534 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Innoviva by 297.7% during the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,795 shares during the last quarter. Danske Bank A S acquired a new position in Innoviva in the third quarter valued at approximately $55,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Innoviva by 49.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 1,197 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in Innoviva in the second quarter valued at approximately $92,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.